Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, announced its participation in the 45th Annual Goldman Sachs Healthcare Conference, from June 10-13, 2024, in Miami.
Carmine Stengone, President and CEO, will engage in a fireside chat on June 10 at 8:40 am ET, with the event webcast live on Contineum’s website. The company will also hold one-on-one meetings with investors throughout the conference.
- Participation in a prestigious event like the Goldman Sachs Healthcare Conference can enhance visibility and credibility.
- Opportunity for one-on-one meetings with investors could attract new investment.
- Live webcast availability offers transparency and accessibility to broader investor community.
- The PR lacks specific updates on financial performance, clinical trial progress, or product development, which are important for investor assessment.
- Absence of new data or developments may lead to unfulfilled investor expectations.
Carmine Stengone, President and Chief Executive Officer of Contineum, will participate in a fireside chat on Monday, June 10, 2024 at 8:40 am Eastern Time, and management will host one-on-one meetings with investors.
A live webcast of the fireside chat will be available on the Investors section of Contineum’s website and a replay will be available following the conclusion of the event.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. PIPE-791 is an LPA1 receptor antagonist which recently completed a Phase 1 healthy volunteer clinical trial to support ongoing clinical development for IPF and progressive multiple sclerosis. PIPE-307, a selective inhibitor of the M1 receptor, is currently in a Phase 2 clinical trial for relapse-remitting multiple sclerosis, and a Phase 2 trial in depression is planned to initiate in 2024. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines.
Contineum is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604132442/en/
Peter Slover
CFO
pslover@contineum-tx.com
Source: Contineum Therapeutics, Inc.
FAQ
When will Contineum Therapeutics participate in the Goldman Sachs Healthcare Conference?
What is the stock symbol for Contineum Therapeutics?
Who will represent Contineum Therapeutics at the Goldman Sachs Healthcare Conference?
What time is the fireside chat with Carmine Stengone at the Goldman Sachs Healthcare Conference?
Will there be a live webcast of Contineum Therapeutics' fireside chat at the conference?
